Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can chemotherapy tame a rare blood cancer? a look back at Real-World outcomes

NCT ID NCT07785180

Knowledge-focused Sponsor: Stemline Therapeutics, Inc. Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Aug 25, 2026 · Last updated Aug 26, 2026 · Updated 1 time

Summary

This study looks back at the medical records of about 140 people with a rare blood cancer called blastic plasmacytoid dendritic cell neoplasm (BPDCN) who received chemotherapy as their first treatment. The goal is to see how effective and safe different chemotherapy regimens are in real-world practice, and to gather data that can be compared with a separate study of the drug tagraxofusp. The study includes adults treated since May 2016, and it will track outcomes like response rates, survival, and side effects.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
chemotherapy regimens (e.g., AML-like, ALL-like, lymphoma-like)
What this could lead to
If this study succeeds, it could provide valuable real-world data on chemotherapy effectiveness in BPDCN, helping guide treatment decisions and serving as a comparison for future studies.
What could go wrong
Because this is a retrospective review of past records, it cannot prove cause and effect. Results may be limited by incomplete data or variations in treatment across institutions.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 140 people

The number the study aims to enrol. It can still change while the study runs.

Started

Oct 2025

Expected to finish

Dec 2027

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Adult participants with BPDCN who have been treated with chemotherapy regimens (at a minimum) as first-line treatment from May 2016 at sites in Europe.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Alive, deceased, or unreachable participants (as permitted by local regulation), aged ≥18 years at the start of first-line treatment for BPDCN, and treated with chemotherapy regimens (at a minimum) as first-line treatment for BPDCN from May 2016 * Diagnosed with BPDCN, based on clinical, laboratory, and imaging (where performed per institutional practice) assessments, with a demonstration of a specific immunophenotype (either by immunohistochemistry or flow cytometry), particularly CD4, CD56, and CD123 * Participants (or their legally authorized representatives) who have signed the informed consent and privacy form, where required as per local regulation Exclusion Criteria: * Participant has received an investigational agent as first-line therapy for BPDCN * Participant has received first-line therapy for BPDCN in an interventional clinical trial

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Blastic plasmacytoid dendritic cell neoplasm (BPDCN) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Blastic Plasmacytoid Dendritic Cell Neoplasm CD4+/CD56+ hematodermic neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Blastic plasmacytoid dendritic cell neoplasm (BPDCN)

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    67 sites in 11 countries. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • A.O. SS Antonio e Biagio e Cesare Arrigo

    RECRUITING

    Alessandria, Italy

  • A.O.O.R. Villa Sofia- Cervello

    RECRUITING

    Palermo, Italy

  • A.O.U. Careggi

    RECRUITING

    Florence, Italy

  • A.O.U. Città della Salute e della Scienza

    RECRUITING

    Torino, Italy

  • A.O.U. Maggiore della Carità

    RECRUITING

    Novara, Italy

  • A.O.U. Policlinico Rodolico San Marco

    RECRUITING

    Catania, Italy

  • A.O.U. San Giovanni di Dio e Ruggi D'Aragona

    RECRUITING

    Salerno, Italy

  • A.O.U. Sant'Andrea

    RECRUITING

    Roma, Italy

  • AO Ordine Mauriziano di Torino

    RECRUITING

    Torino, Italy

  • ASST Grande Ospedale Metropolitano Niguarda

    RECRUITING

    Milan, Italy

  • ASST Spedali Civili

    RECRUITING

    Brescia, Italy

  • ASUFC P.O. Santa Maria della Misericordia

    RECRUITING

    Udine, Italy

  • Aarhus University Hospital

    RECRUITING

    Aarhus, Denmark

  • Amsterdam UMC

    RECRUITING

    Amsterdam, Netherlands

  • Azienda Ospedale-Università di Padova

    RECRUITING

    Padova, Italy

  • Azienda Ospedaliera Universitaria Federico II

    RECRUITING

    Naples, Italy

  • Azienda Ospedaliero Universitaria Consorziale Policlinico

    RECRUITING

    Bari, Italy

  • Centre Hospitalier Universitaire Besancon

    RECRUITING

    Besançon, France

  • Centre Hospitalier Universitaire Poitiers

    RECRUITING

    Poitiers, France

  • Centre Hospitalier Universitaire de Bordeaux - Hôpital Haut-Lévêque

    RECRUITING

    Bordeaux, France

  • Centre Hospitalier Universitaire de Nice

    RECRUITING

    Nice, France

  • Centre Hospitalier Universitaire de Tours

    RECRUITING

    Tours, France

  • Evaggelismos Hospital, Dept. Hematology-Lymphoma and BMT Unit

    RECRUITING

    Athens, Greece

  • Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico

    RECRUITING

    Milan, Italy

  • Fondazione IRCCS Policlinico San Matteo

    RECRUITING

    Pavia, Italy

  • Fondazione Policlinico Universitario A. Gemelli IRCCS

    RECRUITING

    Roma, Italy

  • Fundacion Jimenez Diaz

    RECRUITING

    Madrid, Spain

  • Gustave Roussy

    RECRUITING

    Villejuif, France

  • Henri Mondor University Hospital

    RECRUITING

    Créteil, France

  • Hospital General Dr Balmis

    RECRUITING

    Alicante, Spain

  • Hospital General de Albacete

    RECRUITING

    Albacete, Spain

  • Hospital Germans Trias i Pujol

    RECRUITING

    Badalona, Spain

  • Hospital La Fe

    RECRUITING

    Valencia, Spain

  • Hospital San Pedro de Alcántara

    RECRUITING

    Cáceres, Spain

  • Hospital Universitario 12 de Octubre

    RECRUITING

    Madrid, Spain

  • Hospital Universitario Central de Asturias

    RECRUITING

    Oviedo, Spain

  • Hospital Universitario De Burgos

    RECRUITING

    Burgos, Spain

  • Hospital Universitario Ramón y Cajal

    RECRUITING

    Madrid, Spain

  • Hospital Universitario Reina Sofia

    RECRUITING

    Córdoba, Spain

  • Hospital de Santa Maria

    RECRUITING

    Lisbon, Portugal

  • Hôpital Avicenne

    RECRUITING

    Bobigny, France

  • IEO Istituto Europeo di Oncologia

    RECRUITING

    Milan, Italy

  • IRCCS Azienda Ospedaliero Universitaria di Bologna

    RECRUITING

    Bologna, Italy

  • Institute of Hematology and Transfusion Medicine

    RECRUITING

    Warsaw, Poland

  • King's College Hospital

    RECRUITING

    London, United Kingdom

  • Klinikum Bremen-Mitte gGmbH

    RECRUITING

    Bremen, Germany

  • Klinikum Chemnitz gGmbH

    RECRUITING

    Chemnitz, Germany

  • Klinikum Oldenburg AöR

    RECRUITING

    Oldenburg, Germany

  • Klinikum rechst der Isar, Technische Universität München

    RECRUITING

    Munich, Germany

  • MD Anderson Cancer Center

    RECRUITING

    Madrid, Spain

  • Maria Sklodowska-Curie National Research Institute of Oncology

    RECRUITING

    Warsaw, Poland

  • National and Kapodistrian University of Athens, General Hospital of Athens

    RECRUITING

    Athens, Greece

  • Odense University Hospital

    RECRUITING

    Odense, Denmark

  • Ospedale S. Maria delle Croci

    RECRUITING

    Ravenna, Italy

  • Oxford University Hospitals NHS Foundation Trust

    RECRUITING

    Oxford, United Kingdom

  • Policlinico Tor Vergata

    RECRUITING

    Roma, Italy

  • Presidio Ospedaliero Santo Spitiro

    RECRUITING

    Pescara, Italy

  • Radboud Universitair Medisch Centrum

    RECRUITING

    Nijmegen, Netherlands

  • Sahlgrenska University Hospital - Section for hematologi and coagulation

    RECRUITING

    Gothenburg, Sweden

  • Saint-Antoine Hospital

    RECRUITING

    Paris, France

  • Saint-Louis Hospital

    RECRUITING

    Paris, France

  • UMC Groningen

    RECRUITING

    Groningen, Netherlands

  • Uniklinikum Leipzig

    RECRUITING

    Leipzig, Germany

  • Uniklinikum Würzburg

    RECRUITING

    Würzburg, Germany

  • University College London Hospitals

    RECRUITING

    London, United Kingdom

  • University Hospital Schleswig Holstein Campus Lübeck

    RECRUITING

    Lübeck, Germany

  • University of Patras

    RECRUITING

    Pátrai, Greece

More trials for these conditions

Other studies related to the condition(s) this trial covers.